<DOC>
	<DOCNO>NCT03043729</DOCNO>
	<brief_summary>Patients locally advanced rectal rectosigmoid cancer stag cT3 CRM-negative MRI receive 6 cycle neoadjuvant treatment mFOLFOX6 ( Arm A ) vs. mFOLFOX6 + aflibercept ( Arm B ) follow surgery .</brief_summary>
	<brief_title>mFOLFOX6 vs. mFOLFOX6 + Aflibercept Neoadjuvant Treatment MRI-defined T3-rectal Cancer</brief_title>
	<detailed_description>Patients locally advanced rectal cancer generally recommend receive preoperative radiotherapy radiochemotherapy . The advantage combined-modality therapy rectal cancer reduce local pelvic recurrence - dread morbid event - rate 10 % . There good quality evidence preoperative radiotherapy reduces local recurrence little impact overall survival . One strategy reduce distant recurrence rate , thereby increase cure rate , would introduce systemic treatment earlier prevent dissemination micrometastases . The present trial design compare two neoadjuvant chemotherapy regimens patient non-metastatic T3 CRM-negative rectal cancer use quality-controlled MRI pelvis main inclusion criterion . This strategy believe reduce acute long-term toxicity cause preoperative radiotherapy administer effective systemic chemotherapy early course disease neoadjuvant chemotherapy .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Age ≥ 18 year day signing inform consent 2 . Signed date informed consent , willing able comply protocol requirement 3 . WHO/ECOG Performance Status ( PS ) 01 4 . Diagnosis rectal adenocarcinoma 5 . Candidate sphinctersparing surgical resection prior neoadjuvant therapy accord primary surgeon , i.e . patient include surgeon indicates need abdominoperineal resection ( APR ) baseline . 6 . Clinical staging base combination follow assessment : Physical examination primary surgeon CT scan chest/abdomen Pelvic MRI Rigid rectoscopy / endoscopic ultrasound ( ERUS ) . Both examination ( i.e . MRI ERUS ) mandatory . 7 . The tumor fulfill follow criterion : No symptomatic bowel obstruction Locally advance rectal rectosigmoid cancer , i.e . low border tumor &gt; 5 cm &lt; 16 cm anal verge determine rigid rectoscopy MRI criterion : 1 . Lower border tumor line define promontorium symphysis , regardless criterion `` &lt; 16 cm anal verge determine rigid rectoscopy '' . 2 . No evidence tumor adjacent ( define within 2 mm ) mesorectal fascia MRI ( i.e . CRM &gt; 2 mm ) 3 . Only T3tumors include , i.e infiltration perirectal fat &lt; 10 mm provide CRM &gt; 2 mm 4 . Note : MRI criterion use definition T3 tumor ( i.e . exclusion T2 T4 situation ) . 8 . Hematological status : Neutrophils ( ANC ) ≥ 2 x 10^9/L Platelets ≥ 100 x 10^9/L Hemoglobin ≥ 9 g/dL ( previous transfusion pack blood cell allow ) 9 . Adequate renal function : Serum creatinine level ≤ 1.5 x upper limit normal ( ULN ) ≤ 1.5 mg/dl Creatinine clearance ≥ 30 ml/min 10 . Adequate liver function : Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alkaline phosphatase &lt; 3 x ULN AST ALT &lt; 3 x ULN 11 . Proteinuria &lt; 2+ ( dipstick urinalysis ) ≤ 1 g/24hour ≤ 500mg/dl 12 . Regular followup feasible 13 . For female patient childbearing potential , negative pregnancy test within 1 week ( 7 Days ) prior start study treatment 14 . Female patient childbearing potential ( i.e . undergo surgical sterilization hysterectomy , bilateral tubal ligation , bilateral oophorectomy postmenopausal least 24 consecutive month ) must commit use high effective appropriate method contraception least 6 month end study treatment combine ( estrogen progestogen contain ) hormonal contraception associate inhibition ovulation , progestogenonly hormonal contraception associate inhibition ovulation , intrauterine device ( IUD ) , intrauterine hormonereleasing system ( IUS ) , bilateral tubal occlusion , vasectomized partner , sexual abstinence . If oral contraception use , barrier method contraception ( e.g . male condom , female condom , cervical cap , diaphragm , contraceptive sponge ) apply additionally 15 . Fertile male patient partner childbearing potential must commit use high effective appropriate method contraception ( detail see ) least 9 month end study treatment . 1 . Distant metastasis ( CT scan thorax abdomen mandatory ) 2. cT2 cT4 tumor ( define MRI criterion ) 3 . Exclusion potentially compromise CRM define MRI criterion ( i.e . &gt; 2 mm distance CRM ) 4 . Prior antineoplastic therapy rectal cancer 5 . History evidence upon physical examination CNS metastasis 6 . Uncontrolled hypercalcemia 7 . Preexisting permanent neuropathy ( NCICTCAE grade ≥ 2 ) 8 . Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) , history hypertensive crisis , hypertensive encephalopathy 9 . Concomitant protocol unplanned antitumor therapy ( e.g . chemotherapy , molecular target therapy , immunotherapy , radiotherapy ) 10 . Treatment investigational medicinal product within 28 day prior study entry 11 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 12 . Treatment CYP3A4 inducer unless discontinue &gt; 7 Days prior randomization 13 . Any follow 3 month prior inclusion : Grade 34 gastrointestinal bleeding Treatment resistant peptic ulcer disease Erosive esophagitis gastritis Infectious inflammatory bowel disease Diverticulitis 14 . Any active infection within 2 week prior study inclusion 15 . Vaccination live , attenuated vaccine within 4 week prior first administration study medication 16 . Other concomitant previous malignancy , except : Adequately treat insitu carcinoma uterine cervix Basal squamous cell carcinoma skin Cancer complete remission &gt; 5 year 17 . Any serious uncontrolled nonmalignant disease , major surgery traumatic injury within last 28 day prior study entry 18 . Pregnant breastfeed woman 19 . Patients know allergy constituent study drug 20 . History myocardial infarction and/or stroke within 6 month prior randomization , NYHA class III IV congestive heart failure 21 . Severe renal insufficiency ( creatinin clearance &lt; 30 ml/min ) 22 . Bowel obstruction 23 . Contraindication assessment MRI 24 . Involvement plan and/or conduct study ( applies Sanofi staff and/or staff Sponsor study site ) 25 . Patient might dependent sponsor , site investigator 26 . Patient incarcerate involuntarily institutionalize court order authority § 40 Abs . 1 S. 3 Nr . 4 AMG 27 . Patients unable consent understand nature , significance implication clinical trial therefore form rational intention light fact [ § 40 Abs . 1 S. 3 Nr . 3a AMG ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>neoadjuvant</keyword>
	<keyword>MRI-defined T3</keyword>
	<keyword>mFOLFOX6</keyword>
	<keyword>Aflibercept</keyword>
</DOC>